Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
List view / Grid view
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Targets for drug discovery can be identified with AI but require validation in vitro. Here’s how this can be done, using hiPSC technology.
1 October 2021 | By Sartorius
Join this roundtable of industry experts as they discuss technologies, best practices and strategies for delivering robust, stable, high-yielding cell lines to accelerate and streamline the drug discovery process.
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
Product hub: High-throughput screening of cyclic peptide libraries for developing drugs to challenging targets
Professor Christian Heinis explains how peptides could offer the next generation of therapeutics and what is required to screen libraries of cyclic peptides.
A picodroplet-based microfluidic method for automating the complete genome-editing workflow. Learn more in this free application note.
Sheraz Gul explores how machine learning and artificial intelligence represent an exciting opportunity for the drug discovery industry, with the potential to develop highly optimised small molecules.
CRISPR libraries can be highly useful for target identification, gene screens and drug discovery. Dr Erik Willems, Senior Manager of Cell Biology at Thermo Fisher Scientific, discusses the company’s CRISPR libraries and the advantages they can offer scientists.
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.
New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.